Genesis Biotechnology Group snaps up NEDP to boost its CRO work

petri dishes in a lab
Genesis Drug Discovery & Development's purchase of New England Discovery Partners comes after the company bought another CRO, NexusPharma, back in the summer. (science photo/Shutterstock)

Genesis Drug Discovery & Development (GD3) has bought up New England Discovery Partners (NEDP) as it looks to boost its synthetic and medicinal chemistry offerings.

The CRO acquisition, financial details of which were not released, also helps GD3 enhance its preclinical drug research and discovery services to its pharma and academia clients.

“NEDP's skilled team of chemists, with almost 250 years of combined pharma and CRO experience, will work synergistically with GD3's existing services around uHTS, computational chemistry, and structural biology,” the company said in a statement.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

“We’re committed to building an industry-leading, fully integrated drug discovery CRO,” said Eli Mordechai, Ph.D., CEO of Genesis Biotechnology Group. “Adding NEDP is another way to differentiate our capabilities in the early drug discovery space. We're significantly enhancing our portfolio around organic and medical chemistry to better serve our industry partners.”

This comes after the company bought another CRO, NexusPharma, back in the summer.

That deal saw GD3 integrate the company’s collection of patient-derived xenograft models, with a focus on personalized medicine, including models for acquired resistance to targeted therapies.

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.